Dr. Simon Thom, of the International Centre for Circulatory Health, Imperial College London, and colleagues published a report in the Sept. 3, 2013, issue of the Journal of the American Medical Association that extols the superiority of treatment of cardiovascular disease with a single pill that combines medications that treat high blood pressure, high cholesterol, and accomplish platelet control.
The need for a single combination drug to control the three major causes of cardiovascular disease is evinced by the poor adherence to a multiple drug regimen in test group sampling. The high costs of taking three or more drugs to control multiple cardiovascular disease threats was another substantial block to patient compliance as demonstrated by the study.
A randomized trial of the single drug therapy involved 2,000 individuals from Britain and India. Half the participants took the single drug combination and half took three or four different drugs to control their cardiovascular disease risks.
The results demonstrated that a single pill regimen that included a blood thinner, a cholesterol lowering medication, a drug that lowered blood pressure, and a beta blocker accomplished a 77 percent compliance rate and a reduction in symptom rate that was 26 percent greater than a multiple drug treatment regimen.
The researchers stress that the cost of a multiple drug in a single pill was substantially lower than multiple pills and that compliance with treatment would be more affordable in low income countries as well as in high income countries.